

Documentation of OEL

Bromoform
CHBr₃
[CAS No. 75-25-2]
OEL-M 1 ppm (10.3 mg/m³)
(proposed in 1997)

1. Bromoform (tribromomethane) is a non-flammable colorless transparent liquid at room temperature, with chloroform-like smell. Molecular weight, 252.8; melting point 9°C, boiling point 149–150°C (for conversion factor and other physico-chemical properties, see Table 1). Industrially, bromoform is used as an agent for geochemical analysis, and heavy fluid ore dressing¹.
2. In the following discussion, the toxicity of bromoform is compared with that of three structurally related chemicals of chloroform (CAS No. 67-66-3), bromodichloromethane (CAS No. 75-27-4) and dibromochloromethane (CAS No. 124-48-1).
3. Bromoform can be absorbed via oral and respiratory routes^{2,3}. The rate of skin penetration of bromoform may be low, by analogy to chloroform⁴. It is known, however, that a toxic dose of methyl bromide can be absorbed through intact human skin⁴. Bromoform, when absorbed, will be exhaled in an unchanged form and also as carbon dioxide^{2,3}, similar to the cases of chloroform, bromodichloromethane and dibromochloromethane^{2,3,5}; the ratios between bromoform and carbon dioxide, and also their ratios over the total dose given varies among the species of experimental animals, e.g., between rats and mice^{2,3} (Table 2).
4. No substantial difference is observed among the LD₅₀ values of the four trihalomethanes when evaluated on an equimolar basis^{6–11} (Table 2).
5. Liver damage was observed when bromoform was given orally to mice at 50, 250 mg/kg/d for 14 d¹². The oral administration to mice at 145, 289 mg/kg/d for 14 d also resulted in liver damage at both of the two doses, and kidney damage at the higher dose¹³.
6. When given orally 5 d/wk for 13 wk, vacuolation of hepatocytes was observed in rats given at 12 mg/d, and in mice at the doses of 200, 400 mg/d.
7. It is common to the four trihalomethanes that the liver and kidney are the major target organs of the toxicity after repeated dosing^{6,9,15}.
8. In an experiment in which male B6C3F₁ mice were given bromoform (diluted in corn oil) at 0, 50, 100 mg/kg/d, female mice at 0, 100, 200 mg/kg/d, and male and female Fischer 344 rats at 0, 100, 200 mg/kg/d for 103 wk, fatty degeneration of the liver was detected in male and female rats and female mice of all bromoform-dosed groups⁶. In the experiment, no dose-dependent increase in occurrence of tumors was observed either in the mice or in the rats except that adenomatous polyps increased dose-dependently the large intestine of the female rats (0/50, 1/50, 6/50; p<0.004)⁶.
9. In carcinogenicity studies with related chemicals, hepatocellular carcinoma was observed in mice given chloroform¹⁶, cancer in the kidney of rats, and adenoma in the liver, the kidney and the thyroid gland of mice given bromodichloromethane⁹, carcinoma and adenoma in the liver and adenoma in the thyroid gland of mice given dibromochloromethane¹⁶ (Table 3).
10. It should be noted that, in these experiments, the dose of chloroform was twice as much as that of other trihalomethanes^{6,9,10,16}. Nevertheless, the results as a whole appear to suggest that carcinogenic potency tends to be weaker with further replacement of chlorine atoms with bromine atoms (i.e., from chloroform to bromoform), with one exception that dibromochloromethane administration induced hepatocellular carcinoma in mice (Table 3). The observation agrees well with the decision of IARC to classify chloroform¹⁷ and bromodichloromethane¹⁸ in Group 2B, and dibromochloromethane¹⁹ and bromoform²⁰ in Group 3.
11. When the evaluation by various agencies/organizations on the carcinogenicity potential of 7 brominated or chlorinated aliphatics which are structurally related to the four trihalomethanes, classification of 1,2-dibromoethane by IARC in Group 2A is the case in which the chemical is given the highest rank in the hazard rating among them, and no agencies/organizations classifies any of the 7 chemicals as a human carcinogen^{22–26} (Table 4).
12. Mutagenicity of bromoform is negative in presence of S₉-mix and mostly negative in absence of S₉-mix in Ames test^{27,28}. The mutagenicity is positive, however, in chromosome aberration studies with cultured mammalian cells^{6,29}, and also in a sister chromatid exchange study in presence of S₉-mix³⁰.
13. Chloroform is negative in Ames test³¹. Bromodichloromethane and dibromochloromethane are either positive or negative in Ames test^{15,16,29,32,33} and positive at least in one of chromosome aberration or sister chromatid exchange studies with cultured mammalian cells^{30,33,34} (Table 3).
14. In a reproduction toxicity study in which bromoform

Table 1. Physicochemical properties of bromoform and other three trihalomethanes

Chemical	Molecular formula	CAS No.	Molecular weight	1 ppm = (mg/m ³)	Appearance	Melting point (°C)	Boiling point (°C)
Chloroform	CHCl ₃	67-66-3	119.39	4.9	Colorless liquid	- 63.5	61.2
Bromodichloromethane	CHBrCl ₂	75-27-4	163.83	6.7	Colorless liquid	- 57.1	90.1
Dibromochloromethane	CHBr ₂ Cl	124-48-1	208.29	8.5	Colorless to pale-yellow liquid	< - 20	119–120
Bromoform	CHBr ₃	75-25-2	252.75	10.3	Colorless liquid	8.3	149.5

Table 2. Metabolism of [¹⁴C]bromoform and other three trihalomethanes when given orally

Chemical	Metabolism
CHCl ₃	In monkeys, rats and mice, the radioactivity was exhaled as unmetabolized and also as CO ₂ . The ratio of the CO ₂ /the unmetabolized was the highest in monkeys, followed by rats and the lowest in mice ^{2, 3}). Exhaled radioactivity was mostly as unmetabolized in monkeys, as unmetabolized and also as CO ₂ in rats, and mostly as CO ₂ in mice.
CHBrCl ₂	In rats and mice, the radioactivity was exhaled as unmetabolized and also as CO ₂ . The ratio of the CO ₂ : the unmetabolized was 14%: 42% of the given dose in rats and 81%: 7% in mice.
CHBr ₂ Cl	Similar to the case of CHBrCl ₂ , except that the ratio of the CO ₂ : the unmetabolized was 18%: 48% in rats and 72%: 12% in mice.
CHBr ₃	Similar to the case of CHBrCl ₂ , except that the ratio of the CO ₂ : the unmetabolized was 4%: 67% in rats and 40%: 6% in mice.

For chemical names, see Table 1.

Table 3. Toxicity profile of bromoform and other three trihalomethanes (Part 1)

Chemical	Oral LD ₅₀ (mg/kg)	Major findings after 13-wk repeated p.o. dosing	Major findings after 2-yr repeated p.o. dosing
CHCl ₃	Rats: 445–1,336 ⁷⁾ Mice: 120–490 ⁸⁾	The major target is liver ¹⁴⁾	Rats (90–100, 180–200 mg/kg/d): Epithelial tumors in males ⁶⁾ Mice (138,277 mg/kg/d for males, 238, 477 mg/kg/d for females): Hepatocellular carcinoma ¹⁶⁾
CHBrCl ₂	Rats: 300–600 ⁹⁾ Mice: 651 ⁹⁾	Rats (19–300 mg/kg/d): Liver and kidney damage ⁹⁾	Rats (50, 100 mg/kg/d): Necrosis and other lesions in liver. Carcinoma in kidney, adenoma of renal tubules and large intestine ⁹⁾ Mice (50, 150 mg/kg/d): Adenoma of thyroid gland, renal tubules, and liver
CHBr ₂ Cl	Rats: 848–1,186 ¹⁰⁾ Mice: 800–1,200 ¹¹⁾	Rats (15–250 mg/kg/d): Liver and kidney damage ¹⁵⁾ Mice (15–250 mg/kg/d): Liver and kidney damage ¹⁵⁾	Rats (40, 80 mg/kg/d): No tumors ¹⁵⁾ Mice (40, 80 mg/kg/d): Hepatocellular carcinoma, adenoma of thyroid gland and liver ¹⁵⁾
CHBr ₃	Rats: 1,147–1,138 ¹⁰⁾ Mice: 933 ⁶⁾	Rats (12–200 mg/kg/d): Vacuolation of hepatocytes ⁶⁾ Mice (25–400 mg/kg/d): Vacuolation of hepatocytes (no change at <200 mg/kg/d ⁶⁾)	Rats (100, 200 mg/kg/d): Adenoma of large intestine ⁶⁾ Mice (50, 100 mg/kg/d): No tumors ⁶⁾

For chemical names, see Table 1.

Table 3. Toxicity profile of bromoform and other three trihalomethanes (Part 2)

Chemical	S ₉ -mix	Mutagenicity			Class. by IARC ^c	Reprod. tox. ^d	Occupational Exposure Limit		
		Ames	CA ^a	SCE ^b			JSOH ^e	ACGIH ^f	DFG ^g
CHCl ₃	Absent	– ³¹⁾			2B ¹⁷⁾	None ³⁶⁾	10 ppm: 2B (49 mg/m ³)	10 ppm: 2B (49 mg/m ³)	10 ppm: 2B (50 mg/m ³)
	Present	+ ³¹⁾							
CHBrCl ₂	Absent	+ ²⁷⁾ , – ³²⁾	+ ³³⁾	+ ³⁰⁾ , – ³³⁾	2B ¹⁸⁾	None ³⁷⁾	–; 2B ^h	–	–
	Present	+ ³³⁾ , – ³²⁾	– ⁹⁾						
CHBr ₂ Cl	Absent	+ ²⁷⁾ , – ¹⁵⁾	– ³⁴⁾	+ ³⁰⁾	3 ¹⁹⁾	None ³⁷⁾	–	–	–
	Present	+ ²⁷⁾ , – ¹⁵⁾	+ ³⁴⁾						
CHBr ₃	Absent	+ ²¹⁾ , – ²⁷⁾	+ ⁶⁾	+ ³⁰⁾	3 ²⁰⁾	None or very weak ³⁵⁾	–	0.5 ppm: A3, S	–; B
	Present	– ²⁷⁾	+ ²⁹⁾	– ⁶⁾					

For chemical names, see Table 1. ^a Chromosome aberration test. ^b Sister chromatid exchange test. ^c Classification by International Agency for Research on Cancer. ^d Reproduction toxicity. ^e Japan Society for Occupational Health²⁴⁾. ^f American Conference of Governmental Industrial Hygienists²⁵⁾. ^g Deutsche Forschungsgemeinschaft²⁶⁾. ^h Provisional.

Table 4. Carcinogenicity hazard classification and occupational exposure limit for related chemicals

Chemical	CAS NO.	IARC ^a	JSOH ^b	ACGIH ^c	DFG ^d	
Bromomethane	CH ₃ Br	74-83-9	–	–	A4, 5 ppm S (A4, 1 ppm S) ^e	B, —
Bromochloromethane	CH ₂ BrCl	74-97-5	–	–	200 ppm	200 ppm
Bromoethane	C ₂ H ₅ Br	74-96-4	3	–	A3, 5 ppm S	A2, —
1,2-Dibromoethane	CH ₂ BrCH ₂ Br	106-93-4	2A	–	A3, —S	A2, —
1,2-Dichloroethane	CH ₂ ClCH ₂ Cl	107-06-2	–	2B, 10 ppm	A4, 10 ppm	A2, —
1,2-Dibromo-3-chloropropane	CH ₂ BrCHBrCH ₂ Cl	96-12-8	2B	–	–	A2, —
2-Bromopropane	CH ₃ CHBrCH ₃	75-26-3	–	–	–	–

^a International Agency for Research on Cancer^{22, 23)}. ^b Japan Society for Occupational Health²⁴⁾. ^c American Conference of Governmental Industrial Hygienists²⁵⁾. ^d Deutsche Forschungsgemeinschaft²⁶⁾. ^e An intended change.

was given to female mice at the doses of 0, 50, 100, 200 mg/kg/d p.o. for one week before mating, 14 wk during mating, and 3 wk after mating. Decreases in body weight and kidney weight, and an increase in liver weight were observed in the females given 100 or 200 mg/kg/d³⁵⁾. No apparent reproduction toxicity was observed, however, in any dosed groups except that the survival rate was reduced in newborns from mothers given 200 mg/kg/d³⁵⁾.

15. No apparent reproduction toxicity was detected in experiments with chloroform, bromodichloromethane or dibromochloromethane^{36, 37)}.
16. Among brominated aliphatic chemicals, reproduction toxicity has been observed in humans exposed to 1,2-dibromomethane^{38, 39)} or 1,2-dibromo-3-chloropropane^{40, 41)}. In addition, toxic effects of 2-bromopropane on the testes and the ovaries were demonstrated both in workers and in rats in recent years^{42–45)}.
17. In summary, it is likely that general toxicity and carcinogenicity of bromoform are similar to and no more potent than that of chloroform. Reproductive

toxicity of bromoform is quite suspicious. Thus, one ppm is proposed as a provisional occupational limit for bromoform.

18. No SKIN notation is given to bromoform. This is, however, primarily due to lack of information, and skin contact with liquid bromoform should be minimized.


References

- 1) Kagaku Kogyo Nippo Press (ed.). Bromoform. In: 13197 Chemical Products. Kagaku Kogyo Nippo Press, Tokyo, 1997; 168 (in Japanese).
- 2) Parra P, Martinez E, Sunol E, Artigas F, Tusell JM, Gelpi E, Albaiges J. Analysis, accumulation and central effects of trihalomethanes. I. Bromoform. Toxicol Environ Chem 1986; 24: 79–91.
- 3) Mink FL, Brown TJ, Rickabaugh J. Absorption, distribution, and excretion of ¹⁴C-trihalomethanes in mice and rats. Bull Environ Contam Toxicol 1986; 37: 752–758.
- 4) Jordi AU. Absorption of methyl bromide through the intact skin. A report of one fatal and two non-fatal cases. J Aviat Med 1953; 24: 536–539.

- 5) Brown DM, Langley PF, Smith D, Taylor DC. Metabolism of chloroform I. The metabolism of [¹⁴C] chloroform by different species. *Xenobiotica* 1974; 4: 151–163.
- 6) National Toxicology Program. Toxicology and carcinogenesis studies of tribromomethane (bromoform) (CAS No. 75-25-2) in F344/N rats and B6C3F₁ mice (gavage studies). NTP Tech Rep Ser No. 350, 1989.
- 7) Kimura ET, Ebert DM, Dodge PN. Acute toxicity and limits of solvent residue for sixteen organic solvents. *Toxicol Appl Pharmacol* 1971; 19: 699–704.
- 8) Hill RN, Clemens TL, Liu DK, Vesell ES, Johnson WD. Genetic control of chloroform toxicity in mice. *Science*. 1975; 190: 159–161.
- 9) National Toxicology Program. Toxicology and carcinogenesis studies of bromodichloromethane (CAS No. 75-27-4) in 344/N rats and B6C3F₁ mice (gavage studies) NTP Rep Ser No. 321, 1987.
- 10) Chu I, Secours V, Marino I, Villeneuve DC. The acute toxicity of four trihalomethanes in male and female rats. *Toxicol Appl Pharmacol* 1980; 52: 351–353.
- 11) Bowman FJ, Borzelleca JF, Munson AE. The toxicity of some halomethanes in mice. *Toxicol Appl Pharmacol* 1978; 44: 213–215.
- 12) Munson AE, Sain LE, Sanders VM, Kauffmann BM, White KL Jr., Page DG., Barnes DW, Borzelleca JF. Toxicology of organic drinking water contaminants; trichloromethane, bromodichloromethane, dibromochloromethane, and tribromomethane. *Environ Health Perspect* 1982; 46: 117–126.
- 13) Condie LW, Smallwood CL, Laurie RD. Comparative renal and hepatotoxicity of halomethanes; bromodichloromethane, bromoform, chloroform, dibromochloromethane and methylene chloride. *Drug Chem Toxicol* 1983; 6: 563–578.
- 14) Japanese Society for Occupational Health (ed.). Chloroform. In: Documentation of Occupational Exposure Limits. Japan Society for Occupational Health, Tokyo, 1994. 95–96.
- 15) National Toxicology Program. Toxicology and carcinogenesis studies of chlorodibromomethane (CAS No. 124-48-1) in F344/N rats and B6C3F₁ mice (gavage studies). NTP Tech Rep Ser No. 282, 1985.
- 16) National Cancer Institute. Report on carcinogenesis bioassay of chloroform. National Technical Information Service, Springfield (PB-264018), 1976.
- 17) International Agency for Research on Cancer. Chloroform. IARC Monogr Eval Carc Risk Chem Hum 1987; Suppl 7: 152–154.
- 18) International Agency for Research on Cancer. Bromodichloromethane. IARC Monogr Eval Carc Risk Hum 1991; 52: 179–212.
- 19) International Agency for Research on Cancer. Chlorodibromomethane. IARC Monogr Eval Carc Risk Hum 1991; 52: 243–268.
- 20) International Agency for Research on Cancer. Bromoform. IARC Monogr Eval Carc Risk Hum 1991; 52: 213–242.
- 21) Haworth S, Lawlor T, Mortelmans K, Speck W, Zeiger E. Salmonella mutagenicity test results for 250 chemicals. *Environ Mutag* 1983; Suppl 1: 3–142.
- 22) International Agency for Research on Cancer. 1,2-Dibromo-3-chloropropane, Ethylene dibromide. IARC Monogr Eval Carc Risk Hum 1987; Suppl 7: 191–192, 204–205.
- 23) International Agency for Research on Cancer. Bromoethane. IARC Monogr Eval Carc Risk Hum 1991; 52: 299–314.
- 24) Japan Society for Occupational Health. Recommendation of occupational exposure limits (1996–1997). *J Occup Health* 1996; 38: 134–147.
- 25) American Conference of Governmental Industrial Hygienists. 1996 TLVs and BEIs. ACGIH, Cincinnati, 1996.
- 26) Deutsche Forschungsgemeinschaft. List of MAK and BAT values 1996. VCH, Weinheim, 1996.
- 27) Varma MH, Ampy FR, Verme K, Talbot WW. In vitro mutagenicity of water contaminants in complex mixtures. *Toxicol Appl Pharmacol* 1988; 8: 243–248.
- 28) Rapson WH, Nazar MA, Butsky VV. Mutagenicity produced by aqueous chlorination of organic compounds. *Bull Environ Contam Toxicol* 1980; 24: 590–596.
- 29) Ishidate M. Tribromomethane. In: Chromosomal Aberration Test In Vitro. Realize Inc., Tokyo, 1983. 558 (in Japanese and in English).
- 30) Morimoto K, Koizumi A. Trihalomethanes induce sister chromatid exchanges in human lymphocytes in vitro and mouse bone marrow cells in vivo. *Environ Res* 1983; 32: 72–79.
- 31) Ueleke E, Werner T, Greim H, Kraemer M. Metabolic activation of haloalkanes and tests in vitro for mutagenicity. *Xenobiotica* 1977; 7: 393–400.
- 32) Khudoley VV, Mizgirev I, Pliss GB. The study of mutagenic activity of 126 compounds. *Arch Geschwulstforsch* 1987; 57: 453–462.
- 33) Strobel K, Grummt T. Aliphatic and aromatic halocarbons as potential mutagenic in drinking water. Part I. Halogenated methanes. *Toxicol Environ Chem* 1987; 13: 205–221.
- 34) Ishidate M. Dibromochloromethane. In: Chromosomal Aberration Test In Vitro. Realize Inc., Tokyo, 1983. 153 (in Japanese and in English).
- 35) Gulati DK, Hope E, Barnes LH, Russell S, Poonacha KB. Bromoform: Reproductive and fertility assessment in Swiss CD-1 mice when administered by gavage (NTP-86-FACB-053). NIEHS Research Triangle Park, NC, 1989.
- 36) Thompson DJ, Warner SD, Robinson VB. Teratology studies of orally administered chloroform in the rat and rabbit. *Toxicol Appl Pharmacol* 1974; 29: 348–357.
- 37) Ruddick JA, Villeneuve DC, Chu I. A teratological assessment of trihalomethanes in the rat. *J Environ Sci Health* 1983; B18: 333–349.
- 38) Schrader SM, Ratcliffe JM, Turner TW, Homnung RW. The use of new field methods of semen analysis in the study of occupational hazards to reproduction: The example of ethylene dibromide. *J Occup Med* 1987; 29: 963–965.

- 39) Whorton D, Krauss RM, Marshall S, Milby TH. Infertility in male pesticide workers. *Lancet* 1977; ii: 1259–1291.
- 40) Whorton D, Milby TH, Krauss RM, Stubbs HA. Testicular function in DBCP exposed pesticide workers. *J Occup Med* 1979; 21: 161–166.
- 41) Glass RI, Lyness RN, Mengle DC, Powell KE, Kahn E. Sperm count depression in pesticide applicators exposed to dibromochloropropane. *Am J Epidemiol* 1979; 109: 346–351.
- 42) Hisanaga N. Recent report on an episode of mass organic solvent poisoning in Korea. *Sangyo Eiseigaku Zasshi* 1996; 38: 36.
- 43) Kim Y, June K, Hwang T, Jung G, Kim H, Park J, Kim J, Park J, Park D, Park S, Choi K, Moon Y. Hematopoietic and reproductive hazards of Korean electronic workers exposed to solvents containing 2-bromopropane. *Scand J Work Environ Health* 1996; 22: 387–391.
- 44) Park J-S, Kim Y, Park DW, Choi KS, Park S-H, Moon Y-H. An outbreak of hematopoietic and reproductive disorders due to solvents containing 2-bromopropane in an electronic factory, South Korea: Epidemiological survey. *J Occup Health* 1997; 39: 138–143.
- 45) Ichihara G, Asaeda N, Kumazawa T, Tagawa Y, Kamijima M, Yu X, Kondo H, Nakajima T, Kitoh J, Yu IJ, Moon H, Hisanaga N, Takeuchi Y. Testicular and hematopoietic toxicity of 2-bromopropane, a substitute for ozone layer-depleting chlorofluorocarbons. *J Occup Health* 1997; 39: 57–63.
- 46) Nakajima T, Shimodaira S, Ichihara G, Asaeda N, Kumazawa T, Iwai H, Ichikawa I, Kamijima M, Yu X, Xie Z, Kondo H, Takeuchi Y. Histopathologic findings of bone marrow induced by 2-bromopropane in male rats. *J Occup Health* 1997; 39: 81–82.
- 47) Kamijima M, Ichihara G, Kitoh J, Tsukamura H, Maeda K, Yu X, Xie Z, Nakajima T, Asaeda N, Hisanaga N, Takeuchi Y. Ovariantoxicity of 2-bromopropane in the non-pregnant female rat. *J Occup Health* 1997; 39: 144–149.
- 48) Omura M, Zhao M, Romero Y, Inoue N. Toxicity of 2-bromopropane on spermatogonia and spermatocyte. *J Occup Health* 1997; 39: 1–2.

Ethyl ether



[CAS No. 60-29-7]

**OEL-M 400 ppm (1,200 mg/m³)
(proposed in 1997)**

1. Ethyl ether (diethyl ether) is a very volatile colorless transparent liquid with so-called 'ether smell': Molecular weight, 74.12; melting point - 116°C; boiling point, 34.6°C. The ether is extremely flammable.
2. Ethyl ether is used as an extractant and a solvent¹⁾ in industries.
3. Ethyl ether has a narcotic potential, as well known through its clinical application for inhalation anesthesia. Ethyl ether, when in contact with air, will form peroxide(s) which is irritative to the respiratory tract. Thus, the irritability of the ether varies depending on its purity, especially depending on the extent of the peroxide(s) formation²⁾. Furthermore the peroxide(s) are explosive, posing a serious problem in work safety²⁾.
4. In 1966, This Society (then The Association) proposed 400 ppm (1,200 mg/m³) as the occupational exposure limit for ethyl ether²⁾. The proposal of this concentration took narcotic action of this chemical into consideration, and probably based on the opinions of Amor³⁾ and Cook⁴⁾ that the working condition is unsatisfactory when the exposure to ethyl

ether is in excess of 500 ppm.

5. According to the experiences in clinical anesthesia, sense of pain and then consciousness will be lost when exposed at 2,800 to 10,000 ppm, and surgical anesthesia will be maintained at about 40,000 ppm⁵⁾. Such experiences suggest that the safety margin at 400 ppm will be several times larger for the former concentration and about 100 times larger for the latter.
6. No opinion against the proposal has ever been expressed since 1966.
7. Thus, there is no positive reason at present to change the occupational exposure limit for ethyl ether from the proposed value of 400 ppm.

References

- 1) Kagaku Kogyo Nippo Press (ed.). Ethyl ether in: 13197 Chemical Products. Kagaku Kogyo Nippo Press, Tokyo, 1997: 379 (in Japanese).
- 2) Japan Society for Occupational Health (ed.). Ethyl ether. In: Documentation of Occupational Exposure Limits. Japan Society for Occupational Health, Tokyo, 1994: 33 (in Japanese).
- 3) Amor AJ. The toxicity of solvents. *Paint Manuf* 1950; 20: 53–58.
- 4) Cook WA. Maximum allowable concentrations of industrial atmospheric contaminants. *Ind Ned* 1945; 14: 936–949.
- 5) Coleman AJ. Inhalational anaesthetic agents. In: H.C. Churchill-Davidson (ed.). *A Practice of Anaesthesia*, Lloyd-Luke, London, 1984: 181–189.